Pheiron
Pheiron is a drug development company that aims to increase the probability of success by utilizing human evidence and causal insights from large human populations. They have developed a proprietary coordinate system of human health, which provides detailed disease signatures to understand disease heterogeneity and progression. Their platform, PheironGPS, uses AI to generate causal human evidence, enabling users to build confidence in discovery, optimize clinical translation, identify opportunities, prioritize targets, select indications, and connect mechanisms to patient populations. The company supports over 2000 diseases, uses 100% human data, and represents over 10 populations. They have a team of scientists, clinicians, and engineers with extensive experience in epidemiology, genetics, and machine learning. Pheiron collaborates with other companies, such as Ribo, to advance drug discovery for specific therapeutic areas like siRNA therapeutics and cardiometabolic diseases. Their work has been published in leading scientific journals.
Pheiron
Pheiron is a drug development company that aims to increase the probability of success by utilizing human evidence and causal insights from large human populations. They have developed a proprietary coordinate system of human health, which provides detailed disease signatures to understand disease heterogeneity and progression. Their platform, PheironGPS, uses AI to generate causal human evidence, enabling users to build confidence in discovery, optimize clinical translation, identify opportunities, prioritize targets, select indications, and connect mechanisms to patient populations. The company supports over 2000 diseases, uses 100% human data, and represents over 10 populations. They have a team of scientists, clinicians, and engineers with extensive experience in epidemiology, genetics, and machine learning. Pheiron collaborates with other companies, such as Ribo, to advance drug discovery for specific therapeutic areas like siRNA therapeutics and cardiometabolic diseases. Their work has been published in leading scientific journals.